BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25540318)

  • 21. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine.
    Cummings C; Stewart M; Stevenson M; Morrow J; Nelson J
    Arch Dis Child; 2011 Jul; 96(7):643-7. PubMed ID: 21415043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Teratogenic effects of antiepileptic drugs: what do we advise patients?
    Yerby MS
    Epilepsia; 1997 Sep; 38(9):957-8. PubMed ID: 9579932
    [No Abstract]   [Full Text] [Related]  

  • 23. Australian pregnancy registry of women taking antiepileptic drugs.
    Vajda F; Lander C; O'brien T; Hitchcock A; Graham J; Solinas C; Eadie M; Cook M
    Epilepsia; 2004 Nov; 45(11):1466. PubMed ID: 15509252
    [No Abstract]   [Full Text] [Related]  

  • 24. [Position Statement of Hungarian Epilepsy League: The use of valproate preparations for epilepsy in pregnancy and in women of childbearing age].
    Janszky J;
    Ideggyogy Sz; 2015 Mar; 68(3-4):143. PubMed ID: 26434203
    [No Abstract]   [Full Text] [Related]  

  • 25. Teratogenicity of antiepileptic drugs and drug specific malformations.
    Kaneko S; Otani K; Kondo T; Fukushima Y; Kan R; Takeda A; Nakane Y
    Jpn J Psychiatry Neurol; 1993 Jun; 47(2):306-8. PubMed ID: 8271575
    [No Abstract]   [Full Text] [Related]  

  • 26. Antiepileptic drugs and teratogenesis. How should patients, doctors and health authorities be counselled?
    Friis ML
    Acta Neurol Scand Suppl; 1983; 94():39-43. PubMed ID: 6410674
    [No Abstract]   [Full Text] [Related]  

  • 27. What can we say to women of reproductive age with epilepsy?
    Penovich P; Gaily E
    Neurology; 2005 Mar; 64(6):938-9. PubMed ID: 15781803
    [No Abstract]   [Full Text] [Related]  

  • 28. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism.
    Smith V; Brown N
    Arch Dis Child Educ Pract Ed; 2014 Oct; 99(5):198. PubMed ID: 24692263
    [No Abstract]   [Full Text] [Related]  

  • 29. Dangers of valproate in pregnancy.
    Wieck A; Jones S
    BMJ; 2018 Apr; 361():k1609. PubMed ID: 29669728
    [No Abstract]   [Full Text] [Related]  

  • 30. Prenatal exposure to sodium valproate is associated with increased risk of childhood autism and autistic spectrum disorder.
    Wood A
    Evid Based Nurs; 2014 Jul; 17(3):84. PubMed ID: 23999195
    [No Abstract]   [Full Text] [Related]  

  • 31. Valproate use during pregnancy was linked to autism spectrum disorder and childhood autism in offspring.
    Singh S
    Ann Intern Med; 2013 Aug; 159(4):JC13. PubMed ID: 24026277
    [No Abstract]   [Full Text] [Related]  

  • 32. Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure.
    Huber-Mollema Y; van Iterson L; Oort FJ; Lindhout D; Rodenburg R
    J Neurol; 2020 Jun; 267(6):1724-1736. PubMed ID: 32112258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy.
    Tomson T; Perucca E; Battino D
    Epilepsia; 2004 Oct; 45(10):1171-5. PubMed ID: 15461670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The longer term outcome of children born to mothers with epilepsy.
    Adab N; Kini U; Vinten J; Ayres J; Baker G; Clayton-Smith J; Coyle H; Fryer A; Gorry J; Gregg J; Mawer G; Nicolaides P; Pickering L; Tunnicliffe L; Chadwick DW
    J Neurol Neurosurg Psychiatry; 2004 Nov; 75(11):1575-83. PubMed ID: 15491979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Stigmata of dysembryogenesis and physical development in children born to mothers with epilepsy].
    Kozhokaru AB; Karlov VA; Zhidkova IA; Serkina AV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(5 Pt 2):52-7. PubMed ID: 23120790
    [No Abstract]   [Full Text] [Related]  

  • 36. Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes.
    Kini U; Adab N; Vinten J; Fryer A; Clayton-Smith J;
    Arch Dis Child Fetal Neonatal Ed; 2006 Mar; 91(2):F90-5. PubMed ID: 16239295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risks of in utero exposure to valproate.
    Meador KJ; Loring DW
    JAMA; 2013 Apr; 309(16):1730-1. PubMed ID: 23613078
    [No Abstract]   [Full Text] [Related]  

  • 38. A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy.
    McVearry KM; Gaillard WD; VanMeter J; Meador KJ
    Epilepsy Behav; 2009 Dec; 16(4):609-16. PubMed ID: 19892603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weighing the risks of valproate in women who could become pregnant.
    Angus-Leppan H; Liu RSN
    BMJ; 2018 Apr; 361():k1596. PubMed ID: 29669717
    [No Abstract]   [Full Text] [Related]  

  • 40. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers.
    Campbell E; Kennedy F; Russell A; Smithson WH; Parsons L; Morrison PJ; Liggan B; Irwin B; Delanty N; Hunt SJ; Craig J; Morrow J
    J Neurol Neurosurg Psychiatry; 2014 Sep; 85(9):1029-34. PubMed ID: 24444855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.